Our Vision:

A world where heavy metal toxicity is treatable. Where a third of the world’s children no longer suffer from the harmful effects of lead poisoning. Where heavy metal pollution does not predetermine health, intelligence, or outcomes in the world’s low-income and vulnerable communities.

Our Mission:

To safeguard human health from the threats posed by radiological hazards and environmental heavy metal pollutants. To improve the lives and futures of our patients around the world by delivering effective and affordable therapies to every person in need. To eliminate the health inequities caused by generations of environmental and social neglect.

1. Are any of your drugs FDA-approved?
   No, our drug products have not been approved by the FDA, and any conclusions regarding safety or efficacy for any use or indication are based solely on preclinical studies in animal models. The FDA has granted an Investigational New Drug application for our lead drug candidate HOPO 14-1 and a Phase 1 clinical trial is ongoing. Full Disclaimer

2. Can you answer questions or provide medical advice about metal toxicity or chelation treatments?
   No, we cannot provide any medical advice. Questions about exposure to or toxicity from heavy metals, courses of treatment, recommended chelators, symptoms related to heavy metal contamination, or any other heath-related topics should be directed to your physician.

3. What can I do to stay informed about your progress?
   For shorter, more frequent updates, you can check the News page of our website, or follow us on Twitter. We also publish more comprehensive updates via our mailing list - please sign up here!

4. When will you be starting clinical trials?
   The Phase 1 clinical trail evaluating safety and pharmacology of HOPO 14-1 has launched, and is being conducted by SRI International. More information is can be found at https://clinicaltrials.gov/ct2/show/NCT05628961

5. Can I sign up to participate in a clinical trial?
   We are not currently enrolling participants in any clinical trials. When we have funding and approval to begin enrolling clinical trials, we will make announcements on our website and via our mailing list - please consider signing up if you would like to be notified.

6. I still have questions - who can I contact for more information?
   Our contact information is here. We regret that due to a large volume of inquiries, it may take us some time to reply depending on the nature of your message. We need to reiterate that HOPO 14-1 is not available for sale or distribution at this time.